BioAtla (BCAB) to Release Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect BioAtla to post earnings of ($0.34) per share for the quarter.

BioAtla (NASDAQ:BCAB) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.01. During the same period in the previous year, the business posted ($0.75) EPS. On average, analysts expect BioAtla to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioAtla Price Performance

BCAB traded up $0.03 during trading on Friday, hitting $1.95. 33,660 shares of the stock traded hands, compared to its average volume of 824,646. The firm has a market capitalization of $94.26 million, a P/E ratio of -0.88 and a beta of 1.06. The firm has a 50-day moving average of $1.87 and a 200 day moving average of $1.90. BioAtla has a 12-month low of $1.14 and a 12-month high of $4.02.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a “market outperform” rating and set a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.